Co-Authors
This is a "connection" page, showing publications co-authored by DIANA BELL and PAUL W GIDLEY.
Connection Strength
2.738
-
Unusual mimicker of odontogenic carcinoma: Primary synovial sarcoma of the temporomandibular joint- a critical role for molecular diagnosis. Pathol Res Pract. 2022 Apr; 232:153824.
Score: 0.836
-
Middle ear adenomatous neuroendocrine tumors: a 25-year experience at MD Anderson Cancer Center. Virchows Arch. 2017 Nov; 471(5):667-672.
Score: 0.601
-
Osteoblastoma of the Temporal Bone in a Child. Otol Neurotol. 2022 02 01; 43(2):e276-e278.
Score: 0.208
-
Uncommon tumors of temporomandibular joint: An institutional experience and review. Head Neck. 2020 08; 42(8):1859-1873.
Score: 0.181
-
Evaluating Perineural Spread to the Intratemporal Facial Nerve on Magnetic Resonance Imaging. Otolaryngol Head Neck Surg. 2019 06; 160(6):1087-1094.
Score: 0.169
-
The First Reported Case of Primary Intestinal-type Adenocarcinoma of the Middle Ear and Review of the Literature. Otol Neurotol. 2017 10; 38(9):e364-e368.
Score: 0.154
-
Achaete-scute homolog 1 expression closely correlates with endocrine phenotype and degree of differentiation in sinonasal neuroendocrine tumors. Ann Diagn Pathol. 2015 Jun; 19(3):154-6.
Score: 0.130
-
Facial Nerve Paralysis due to a Pleomorphic Adenoma with the Imaging Characteristics of a Facial Nerve Schwannoma. J Neurol Surg Rep. 2014 Aug; 75(1):e84-8.
Score: 0.121
-
Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone): sine qua non radiology-pathology and the University of Texas MD Anderson Cancer Center experience. Ann Diagn Pathol. 2011 Apr; 15(2):117-23.
Score: 0.096
-
Distinct immune signature predicts progression of vestibular schwannoma and unveils a possible viral etiology. J Exp Clin Cancer Res. 2022 Oct 04; 41(1):292.
Score: 0.054
-
Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.
Score: 0.053
-
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
Score: 0.050
-
Surgical management of carcinomas of the infratemporal fossa and skull base: patterns of failure and predictors of long-term outcomes. J Neurosurg. 2021 05 01; 134(5):1392-1398.
Score: 0.046
-
Multimodality Treatment of Skull Base Chondrosarcomas: The Role of Histology Specific Treatment Protocols. Neurosurgery. 2017 Sep 01; 81(3):520-530.
Score: 0.038